Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163698 | 0.87 | CYP1A2 (0.39) | SMN1; SMN2CYP1A2MAPK1HRH3ALDH1A1 | |
| SCHEMBL3163705 | 0.87 | CYP1A2 (0.39) | SMN1; SMN2CYP1A2MAPK1HRH3ALDH1A1 | |
| SCHEMBL1570988 | 0.80 | HPGD (0.41) | SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16335347 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2MAPK1HRH3ALDH1A1 | |
| SCHEMBL4704889 | 0.76 | OPRM1 (0.33) | SMN1; SMN2CYP1A2MAPK1KMT2AMEN1 | |
| SCHEMBL4326132 | 0.71 | CYP1A2 (0.48) | SMN1; SMN2CYP1A2MAPK1HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1570743 | 0.70 | CXCR4 (0.46) | SMN1; SMN2CYP1A2MAPK1HRH3TDP1 | |
| SCHEMBL1570929 | 0.68 | KMT2A (0.44) | SMN1; SMN2CYP1A2MAPK1HRH3ALDH1A1 | |
| SCHEMBL4322770 | 0.67 | CYP1A2 (0.43) | SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT | |
| SCHEMBL3642681 | 0.67 | MEN1 (0.40) | SMN1; SMN2CYP1A2MAPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307387-B1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | SMN1; SMN2 4376/4885CYP1A2 1217/4885MAPK1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.